4D Molecular Therapeutics: A Smart Bet On Long-Term VEGF Suppression
D Molecular Therapeutics is undervalued, with its lead candidate 4D-150 showing potential. Click here to find out why I rate ...
Pharm Exec2d
Challenges in Developing T Cell Engagers
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro talks about the challenges faced in developing T cell engagers.
Pharm Exec5d
How DiversImmune & MultiMab Compare to Traditional Antibody Discovery Methods
In this part of his Pharmaceutical Executive video interview, Ian Chan, CEO of Abpro discusses the advantages of their DiversImmune and MultiMab platforms for antibody discovery and engineering.